Dr. Kevin Conners
What are Polysaccharides?
A polysaccharide is a large molecule made of many smaller monosaccharides. Monosaccharides are simple sugars, like glucose. Special enzymes bind these small monomers together creating large sugar polymers, or polysaccharides. Depending on their structure, polysaccharides can have a wide variety of functions in nature. Some polysaccharides are used for storing energy, some for sending cellular messages, and others for providing support to cells and tissues. We are more interested in the types of polysaccharides that stimulate immune function. Let’s see how that’s done.
Their Effects on Immune Function
Certain polysaccharides have been called “immunomodulators” because they have been identified to have profound effects in the regulation of immune responses during the progression of infectious diseases and even cancer. They stimulate influence innate and cell-mediated immunity through interactions with T cells, monocytes, macrophages, and polymorphonuclear lymphocytes. In short, specific polysaccharides are wonderful at stimulating immune responses.
What are the BEST Polysaccharides to do so?
Poly = many, as in a chain of saccharide molecules. The number of saccharides in each chain are what defines the molecule and determines how it works in the body. The inner leaf of the Aloe plant has the greatest concentration of beneficial polysaccharides yet discovered. The immune-stimulating, cancer-killing component of Aloe was determined to be an acetylated polymannan called ACEMANNAN. Acemannan works by stimulating the body’s own immune system to help it heal itself!
The Problem, and Solution, with Acemannan
Numerous studies have been published about the benefits of acemannan and the Aloe plant. As usual, when this happens, sales of Aloe rise to consumers wanting the immune-stimulating benefits. The problem is that the acemannan (the active, beneficial component) is NOT stable! UGH! Millions of dollars a year spent on Aloe products that, though other benefits may still avail, the immune-stimulating, cancer-killing properties simply no longer exist (due to acemannan’s instability).
However, thank goodness, a research team discovered not only how to stabilize acemannan so it can be capsulized and utilized by the body, but they discovered the best chain length (50-400) of polysaccharides to give the most immune-stimulating properties. EvolvImmun holds the patent on the only stabilized, correct-chain polysaccharide available for human consumption.
An Animal Study
Forty-three dogs and cats with spontaneous tumors were treated with the immunostimulating polysaccharide acemannan by intraperitoneal and intralesional routes of administration. Tumors from 26 of these animals showed histopathological (microscopically looking at the cells) evidence of immunological attack as shown by marked necrosis or lymphocytic infiltration. In lay-man’s terms, this means that, as the tumors were viewed under the microscope, the tumor cells were dying. Thirteen showed moderate to marked tumor necrosis (tumor cell death) or liquefaction. Twenty-one demonstrated lymphoid infiltration (the immune system was beginning to attack the tumor), and seven demonstrated encapsulation (the body walled-off the tumor). Twelve animals showed obvious clinical improvement as assessed by tumor shrinkage, tumor necrosis, or prolonged survival; these included five of seven animals with fibrosarcomas (quite serious, aggressive cancers). “It is believed,” said the scientists that published the study, “that acemannan exerts its antitumor activity through macrophage activation and the release of tumor necrosis factor, interleukin-1, and interferon.” This means that acemannan helps the body kill the tumor by stimulating the main killing mechanisms of the immune system. (2)
A Human Study
Most human cancer studies will only get their funding if the study couples chemotherapy along with the natural substance. But, that’s okay, it still gives us wonderful data. A study on the polysaccharides from aloe on 240 patients with cancer revealed, “the analysis of tumor immunobiology suggest the possibility of biologically manipulating the efficacy and toxicity of cancer chemotherapy by endogenous or exogenous immunomodulating substances.”
The Polysaccharides in Aloe make it one of the most important plants exhibiting anticancer activity and its antineoplastic property is due to at least three different mechanisms, based on antiproliferative, immunostimulatory and antioxidant effects. The anti-proliferative action is determined by anthracenic and antraquinonic molecules, while the immunostimulating activity is mainly due to acemannan.
Patients and Methods: A study was planned to include 240 patients with metastatic solid tumor who were randomized to receive chemotherapy with or without Aloe. According to tumor histotype and clinical status, lung cancer patients were treated with cisplatin and etoposide or weekly vinorelbine, colorectal cancer patients received oxaliplatin plus 5-fluorouracil (5-FU), gastric cancer patients were treated with weekly 5-FU and pancreatic cancer patients received weekly gemcitabine. Aloe was given orally at 10 ml thrice/daily.
Results: The percentage of both objective tumor regressions and disease control was significantly higher in patients concomitantly treated with Aloe than with chemotherapy alone, as well as the percent of 3-year survival patients.
Conclusion: This study seems to suggest that Aloe may be successfully associated with chemotherapy to increase its efficacy in terms of both tumor regression rate and survival time. (3)
I will be writing more on this subject as this product has been partly responsible for helping me achieve remission in my Stage 4 Cancer.
(1) Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biologic Function. Arthur O. Tzianabos
(2) Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. https://www.altmetric.com/details/13929345
(3) A Randomized Study of Chemotherapy VersusBiochemotherapy with Chemotherapy plus Aloe arborescens in Patients with Metastatic Cancer, PAOLO LISSONI, FRANCO ROVELLI, FERNANDO BRIVIO, et al. In Vivo January-February 2009 vol. 23 no. 1 171-175